Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Conditions
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
Interventions
- DRUG: REL-1017
- DRUG: Placebo
Sponsor
Relmada Therapeutics, Inc.
Collaborators